STE STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1757898 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.1%
TTM net income YoY20.1%
TTM EPS YoY21.7%
Revenue 3-yr CAGR8.6%
Net income 3-yr CAGR14.6%
Margins
Gross margin44.6%
Operating margin19.0%
Net margin13.4%
FCF margin15.2%
EBITDA margin27.0%
Returns
ROE11.6%
ROA7.8%
ROIC (approx.)10.0%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.26x
Current ratio2.05x
Interest coverage20.53x
Cash quality & payout
Operating cash flow / net income1.56x
Accruals ratio-4.4%
Payout ratio30.5%
Capex / revenue5.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.94B | $5.46B |
| Cost of revenue | $3.31B | $3.06B |
| Gross profit | $2.63B | $2.40B |
| R&D expense | $112.90M | $107.60M |
| SG&A expense | $1.41B | $1.33B |
| Operating income | $1.10B | $866.60M |
| Interest expense | $60.70M | $86.30M |
| Pretax income | $1.05B | $796.20M |
| Income tax | $262.20M | $184.70M |
| Net income | $782.30M | $614.60M |
| EBITDA | $1.59B | $1.34B |
| EPS (basic) | 7.97 | 6.24 |
| EPS (diluted) | 7.93 | 6.20 |
| Dividends declared per share | 2.46 | 2.23 |
| Weighted avg. shares (diluted) | 98.70M | 99.10M |
| Balance sheet | ||
| Cash & equivalents | $439.60M | $171.70M |
| Receivables | $1.09B | $1.04B |
| Inventory | $631.80M | $581.30M |
| Current assets | $2.39B | $2.00B |
| PP&E, net | $2.16B | $1.96B |
| Goodwill | $4.19B | $4.10B |
| Intangibles | $1.62B | $1.85B |
| Total assets | $10.74B | $10.15B |
| Current liabilities | $1.15B | $1.02B |
| Short-term debt | $118.90M | $125.00M |
| Long-term debt | $1.81B | $1.92B |
| Total debt | $1.93B | $2.04B |
| Total liabilities | $3.54B | $3.53B |
| Shareholders' equity | $7.18B | $6.60B |
| Net debt | $1.49B | $1.87B |
| Shares outstanding | 97.80M | 98.30M |
| Cash flow statement | ||
| Operating cash flow | $1.34B | $1.15B |
| Capital expenditure | $369.00M | $370.10M |
| Free cash flow | $972.40M | $778.00M |
| Investing cash flow | -$512.50M | $388.80M |
| Financing cash flow | -$568.20M | -$1.57B |
| Depreciation & amortization | $486.50M | $476.20M |
| Stock-based compensation | $61.70M | $57.40M |
| Dividends paid | $241.80M | $219.90M |
| Share buybacks | $235.50M | $211.30M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.